Submaximal Versus Maximal Isometric Tongue Training After Stroke
NCT07922811, Not applicable, Completed, Necmettin Erbakan University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Submaximal Versus Maximal Isometric Tongue Training After Stroke | ClinicalTrials.gov |
| NCT number | NCT07922811 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 38 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Necmettin Erbakan University | ClinicalTrials.gov |
| Conditions | Stroke, Deglutition Disorder | ClinicalTrials.gov |
| Interventions | Isometric tongue resistance training at 80% 1RM, Isometric tongue resistance training at 100% 1RM | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Posterior maximum isometric tongue pressure | Baseline and 6 weeks | Highest of three maximal tongue-to-palate presses at the posterior tongue (10 mm anterior to the circumvallate papillae), measured in kilopascals (kPa) with the Iowa Oral Performance Instrument. | ClinicalTrials.gov |
| Secondary | Anterior maximum isometric tongue pressure | Baseline and 6 weeks | Highest of three maximal tongue-to-palate presses at the anterior tongue (10 mm posterior to the tongue tip), measured in kPa with the Iowa Oral Performance Instrument. | ClinicalTrials.gov |
| Secondary | Anterior tongue endurance | Baseline and 6 weeks | Longest time (seconds) for which participants sustained 50% of the anterior maximum pressure obtained in the same session, measured with the Iowa Oral Performance Instrument. | ClinicalTrials.gov |
| Secondary | Posterior tongue endurance | Baseline and 6 weeks | Longest time (seconds) for which participants sustained 50% of the posterior maximum pressure obtained in the same session, measured with the Iowa Oral Performance Instrument. | ClinicalTrials.gov |
| Secondary | Penetration-Aspiration Scale score, puree | Baseline and 6 weeks | Airway protection during a 10-mL IDDSI Level 3 (puree) bolus on fibreoptic endoscopic evaluation of swallowing; 8-point scale from 1 (no airway entry) to 8 (silent aspiration); lower scores are better. | ClinicalTrials.gov |
| Secondary | Penetration-Aspiration Scale score, thin liquid | Baseline and 6 weeks | Airway protection during a 10-mL IDDSI Level 0 (thin liquid) bolus on fibreoptic endoscopic evaluation of swallowing; 8-point scale from 1 to 8; lower scores are better. | ClinicalTrials.gov |
| Secondary | Vallecular residue (Yale Pharyngeal Residue Severity Rating Scale) | Baseline and 6 weeks | Residue in the valleculae after a puree bolus on fibreoptic endoscopic evaluation of swallowing; 5-point scale from 1 (none) to 5 (severe); lower scores are better. | ClinicalTrials.gov |
| Secondary | Pyriform sinus residue (Yale Pharyngeal Residue Severity Rating Scale) | Baseline and 6 weeks | Residue in the pyriform sinuses after a puree bolus on fibreoptic endoscopic evaluation of swallowing; 5-point scale from 1 (none) to 5 (severe); lower scores are better. | ClinicalTrials.gov |
| Secondary | Functional Oral Intake Scale | Baseline and 6 weeks | Level of oral intake on a 7-point scale from 1 (nothing by mouth) to 7 (total oral diet without restrictions); higher scores are better. | ClinicalTrials.gov |
| Secondary | Swallowing-related quality of life (T-SWAL-QOL) | Baseline and 6 weeks | Total score on the Turkish version of the Swallowing Quality of Life Questionnaire (44 items, each scored 1 to 5; total score range 44 to 220); higher scores indicate better swallowing-related quality of life. | ClinicalTrials.gov |
| Other | Tongue pressure at follow-up | 10 weeks (4 weeks after the end of training) | Anterior and posterior maximum isometric tongue pressure (kPa), Iowa Oral Performance Instrument; assessed in the two training arms only. | ClinicalTrials.gov |
| Other | Tongue endurance at follow-up | 10 weeks (4 weeks after the end of training) | Anterior and posterior tongue endurance (seconds) at 50% of the same-session maximum, Iowa Oral Performance Instrument; assessed in the two training arms only. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)